概括
异索二酸盐 (ISDN) 最初有效治疗心痛,但随着持续使用,耐受性会发展. 在患有慢性稳定性胸痛的患者中,N-乙半氨酸不会逆转这种酸盐耐受性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性稳定性胸痛是一种常见的疾病,其特征是由于心肌缺血引起的胸痛.
- 酸盐血管扩张剂,如异类二酸盐 (ISDN),经常用于心痛管理.
- 对酸盐的耐受性发展可能会限制它们的长期疗效.
研究的目的:
- 评估异索二酸盐 (ISDN) 对慢性稳定性心痛患者的血液动力学和抗性影响.
- 调查N-乙半氨酸是否可以逆转酸盐耐受性.
- 评估持续的ISDN治疗对运动耐受性的影响.
主要方法:
- 12名患有慢性稳定性胸痛的患者每天四次接受30毫克ISDN.
- 在初始剂量后和治疗7-10天后评估了血液动力学和抗血管效应.
- 在持续治疗期间,在N-乙半氨酸或盐水输注之前和之后进行运动测试以评估运动耐受性.
主要成果:
- 最初的ISDN疗法产生了显著的血液动力学和抗血管效应.
- 持续治疗导致血液动力学效应减弱,并在剂量后3小时减少抗风脉的益处.
- 服用N-乙半氨酸并没有逆转酸盐耐受性,血液动力学发现或运动耐受性没有改善.
结论:
- 减少硫基组 (N-乙半氨酸) 的短期使用不会逆转对ISDN的耐受性.
- 酸盐耐受性仍然是慢性稳定性心痛管理的重大临床挑战.
- 需要进一步的研究来确定克服酸盐耐受性的有效策略.
相关概念视频
2° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


